posted
AlphaRx Announces Completion of Phase II Clinical Trial for Indaflex Monday March 5, 8:00 am ET
MARKHAM, Ontario, March 5, 2007 (PRIME NEWSWIRE) -- AlphaRx (OTC BB:ALRX.OB - News) announced today the completion of the treatment phase of the double-blind, placebo & vehicle-controlled, randomized and multi-center Phase II clinical trial, to measure the efficacy and safety of Indaflex(tm) for the treatment of Osteoarthritis of the knee. Currently, no prescription strength topical NSAID for the treatment of arthritis is approved for sale in the U.S. ADVERTISEMENT
Following data validation and analysis, the Company expects to report top-line trial results by the end of March 2007.
In April 2006, AlphaRx licensed Indaflex to Proprius Pharmaceuticals, Inc. Under the terms of the agreement, AlphaRx is eligible to receive milestone payments of up to $116 million for the successful development and commercialization of Indaflex, as well as double-digit royalties on worldwide sales. In addition, Proprius has assumed all clinical development costs.
About Indaflex
Indaflex is AlphaRx's topical NSAID (Non-Steroidal Anti-inflammatory Drug) formulation under clinical development for the treatment of arthritis symptoms. Osteoarthritis is the most common chronic disease in North America and afflicts an estimated 10% of the world's population. Indaflex's active ingredient, Indomethacin, has a long-standing and proven clinical treatment record. With AlphaRx's enhanced proprietary delivery system, the company believes its' clinical effectiveness will be significantly enhanced compared to other topical preparations. Topical Indaflex delivery, the company hopes, may circumvent the significant GI side-effects commonly found with orally ingested NSAID's.
About AlphaRx Inc.
AlphaRx is a clinical stage pharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including arthritis, tuberculosis, ocular infection and inflammation, pneumonia and sepsis.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
AlphaRx's Nanoparticle Formulation of Antituberculosis Drug Shows Promise in Mice Infected With TB (Mycobacterium Tuberculosis) Tuesday February 20, 8:00 am ET
A leading Chinese TB research institute evaluated the efficacy of the Company's nanoparticle-encapsulated Streptomycin administered 2 times a week versus that of daily nonencapsulated drug against Mycobacterium tuberculosis infection in mice. Both treatments significantly reduced the bacterial count and mortality, suggesting that AlphaRx's nanoparticle drug delivery system has potential in the treatment of tuberculosis.
MARKHAM, Ontario, Feb. 20, 2007 (PRIME NEWSWIRE) -- AlphaRx (OTC BB:ALRX.OB - News) is pleased to announce pre-clinical data on Streptomycin encapsulated in the company's Nano Drug Delivery Platform for the treatment of Tuberculosis. Streptomycin is a well-known antibiotic, mainly used to treat tuberculosis. Standard treatment for TB as recommended by the World Health Organization, is Streptomycin 1,000 mg administered once a day by intra-muscular injection initially, and then reducing to two or three times a week after the first 2-4 months.
ADVERTISEMENT
Pre-clinical studies are being conducted at the Beijing Tuberculosis and Thoracic Tumor Research Institute. In a murine model of tuberculosis, Streptomycin encapsulated in the company's Nano Drug Delivery platform administrated by injection of 100mg/kg, twice a week, is as effective as injecting 200mg/kg, five times a week in a conventional formulation in terms of bacteria reduction and mortality. The 80% reduction in dosage (from 1000mg/kg to 200mg/kg) per week is significant, in that it may reduce potential toxicity effects of Streptomycin. Furthermore, the reduction in treatment frequency may result in enhanced patient compliance. A second study to decrease the total dosage to 100mg/kg per week and the treatment frequency to once per week, will commence shortly.
The Company is very pleased with the results of this study and believes that drugs loaded in its Nano Drug Delivery platforms may improve efficacy, reduce side-effects and increase patient compliance. The Company's Nano Drug Delivery platforms are versatile and applicable to many small molecule drug candidates. Currently, the Company has six nano products in the development pipeline, with an estimated annual market sales potential of over US$7.0 Billion dollars.
The Company looks forward to reporting more pre-clinical results on its infectious disease program as they become available.
Mycobacterium tuberculosis (TB) is the leading cause of death among HIV positive and infected patients in the United States. Additionally, TB affects one third of the world's population. A traditional TB treatment regimen requires long treatment times due to poor cellular antibiotic penetration and as a result, patient compliance tends to be low. The Company believes that by successfully increasing intracellular antibiotic concentration, drug efficacy may be substantially improved.
About AlphaRx Inc.
AlphaRx is a clinical stage biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including arthritis, tuberculosis, ocular infection and inflammation, pneumonia and sepsis.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
-------------------------------------------------------------------------------- Source: AlphaRx Inc.
beststocks
posted
some volume will move this very quick.
investorz
posted
stocktrader22 Member
Icon 1 posted February 23, 2007 21:57 Profile for stocktrader22 Send New Private Message Edit/Delete Post Reply With Quote MTIV
I saw it at .0001 weeks ago. I looked at filings, and new it was a gem immediately. Only 1.8 million was available in the whole float!!!! and the stock wasnt active at all so it was impossible to get in because of the grey sheets. I called the broker to try and get shares, but my order never filled.
.0001 in two days straight up to .51
$100 investment = $510,000
Incredible, too bad.
-------------------- Disclaimer: Nothing I say is a recommendation that you purchase, sell or hold any security.
------------------------------------------------- The above message is not mine obviously. Can someone please explain how one finds stocks like the one mentioned above? Any ideas on how to find these so called "gems?"
posted